SI0796623T1 - Farmacevtski pripravek za zdravljenje motenj koagulacije krvi - Google Patents

Farmacevtski pripravek za zdravljenje motenj koagulacije krvi

Info

Publication number
SI0796623T1
SI0796623T1 SI9730711T SI9730711T SI0796623T1 SI 0796623 T1 SI0796623 T1 SI 0796623T1 SI 9730711 T SI9730711 T SI 9730711T SI 9730711 T SI9730711 T SI 9730711T SI 0796623 T1 SI0796623 T1 SI 0796623T1
Authority
SI
Slovenia
Prior art keywords
prothrombin
factor
composition
pro
purified
Prior art date
Application number
SI9730711T
Other languages
English (en)
Inventor
Peter Dr. Turecek
Hans-Peter Prof. Schwarz
Johann Dr. Eibl
Original Assignee
Baxter Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT51896A external-priority patent/AT404673B/de
Priority claimed from AT157396A external-priority patent/AT407116B/de
Priority claimed from AT167396A external-priority patent/AT408612B/de
Application filed by Baxter Aktiengesellschaft filed Critical Baxter Aktiengesellschaft
Publication of SI0796623T1 publication Critical patent/SI0796623T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
SI9730711T 1996-03-20 1997-03-18 Farmacevtski pripravek za zdravljenje motenj koagulacije krvi SI0796623T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT51896A AT404673B (de) 1996-03-20 1996-03-20 Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
AT157396A AT407116B (de) 1996-09-04 1996-09-04 Pharmazeutisches präparat zur behandlung von blutgerinnungsstörungen
AT167396A AT408612B (de) 1996-09-20 1996-09-20 Verwendung von mindestens 2 gerinnungsfaktoren zur herstellung eines pharmazeutischen präparats
EP97890051A EP0796623B1 (de) 1996-03-20 1997-03-18 Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen

Publications (1)

Publication Number Publication Date
SI0796623T1 true SI0796623T1 (sl) 2005-10-31

Family

ID=27146406

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730711T SI0796623T1 (sl) 1996-03-20 1997-03-18 Farmacevtski pripravek za zdravljenje motenj koagulacije krvi

Country Status (12)

Country Link
US (5) US5866122A (sl)
EP (1) EP0796623B1 (sl)
JP (1) JPH1045620A (sl)
AT (1) ATE296109T1 (sl)
AU (3) AU725442B2 (sl)
CA (1) CA2200394A1 (sl)
CZ (1) CZ81997A3 (sl)
DE (1) DE59712322D1 (sl)
DK (1) DK0796623T3 (sl)
ES (1) ES2241030T3 (sl)
HU (1) HUP9700603A3 (sl)
SI (1) SI0796623T1 (sl)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59712322D1 (de) * 1996-03-20 2005-06-30 Baxter Ag Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen
AT409334B (de) * 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
ATA159597A (de) * 1997-09-19 2000-09-15 Immuno Ag Präparat zur behandlung von blutgerinnungsstörungen
HUP0101137A3 (en) 1998-04-10 2003-03-28 Japan Tobacco Inc Anticoagulant amidines and their pharmaceutical use
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
DE19923027C2 (de) * 1999-05-19 2002-09-19 Aventis Behring Gmbh Verfahren zur Inaktivierung von Viren
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6689615B1 (en) 2000-10-04 2004-02-10 James Murto Methods and devices for processing blood samples
DK1351705T3 (da) * 2001-01-10 2009-11-02 Us Army Med Res Mat Command Sammensætninger til behandling af blödning med aktiveret faktor VIIA i kombinantion med fibrinogen
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
WO2003039581A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
EP1446151A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and thrombomodulin polypeptides
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US20080057059A1 (en) * 2001-11-09 2008-03-06 Novo Nordisk Healthcare A/G Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein S Inhibitors
EP1446152A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors
EP1446145A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides
US20030118580A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and thrombomodulin polypeptides
EP1446148A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk A/S Pharmaceutical composition comprising a factor vii polypeptide and epsilon-aminocapronic acid
WO2003072135A2 (en) * 2002-02-26 2003-09-04 North Shore-Long Island Jewish Research Insitute Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors
US20060233786A1 (en) * 2002-05-23 2006-10-19 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
SE519974C2 (sv) * 2002-06-03 2003-05-06 Cemvac System Ab Anordning för utmatning av en monomer till en med en polymer förfylld blandningsanordning för tillredning av bencement
SE0203552D0 (sv) * 2002-12-02 2002-12-02 Biovitrum Ab Thrombin concentration
SE0203551D0 (sv) * 2002-12-02 2002-12-02 Biovitrum Ab Prothrombin purification
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
JP2007530586A (ja) 2004-03-25 2007-11-01 ザ ファインスタイン インスティテュート フォー メディカル リサーチ 神経性止血法
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US7214647B2 (en) * 2004-07-29 2007-05-08 Texas United Chemical Company, Llc. Method of increasing the low shear rate viscosity of well drilling and servicing fluids containing calcined magnesia bridging solids, the fluids and methods of use
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CN101124012B (zh) 2004-12-27 2012-09-05 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病的装置
CN101198696B (zh) * 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
EP1935429A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
US8206967B2 (en) * 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
WO2009146030A1 (en) * 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
CN102215909B (zh) 2008-11-18 2014-09-10 赛博恩特医疗器械公司 优化用于消炎刺激的电极放置的装置和方法
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8788034B2 (en) 2011-05-09 2014-07-22 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
FR2946348B1 (fr) * 2009-06-05 2011-08-05 Lab Francais Du Fractionnement Procede de preparation d'une composition de complexe prothrombique a haut degre de purete
WO2010144578A2 (en) 2009-06-09 2010-12-16 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
WO2011079309A2 (en) 2009-12-23 2011-06-30 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
EP2624859B1 (en) 2010-10-06 2017-03-01 Medimmune Limited Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
BR112014004890A8 (pt) * 2011-08-30 2018-02-06 Acad Medisch Ct Bactéria, composição farmacêutica, alimentícia ou de ração, e, uso da bactéria
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
CA2874290C (en) 2012-06-12 2020-02-25 Ferrosan Medical Devices A/S Dry haemostatic composition
US10001495B2 (en) * 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
CN111508557B (zh) * 2013-06-20 2024-03-26 武田药品工业株式会社 药物动力学药物给药方案设备和方法
WO2014202760A2 (en) 2013-06-21 2014-12-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
EP3079731B1 (en) 2013-12-11 2018-08-08 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
TWI653047B (zh) * 2014-03-14 2019-03-11 百特製藥公司 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物
CA2960309A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
AU2016224834B2 (en) 2015-02-25 2021-12-16 Omrix Biopharmaceuticals Ltd. Method for purifying and quantifying thrombin and its degradation polypeptides
BR112017027695A2 (pt) 2015-07-03 2018-09-04 Ferrosan Medical Devices As seringa para retenção e mistura de primeira e segunda substâncias
AU2017205364B2 (en) * 2016-01-07 2021-03-04 Eio Biomedical Ltd Methods, compositions and kits for reducing tissue adhesions
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405107B1 (en) 2016-01-20 2023-04-12 Setpoint Medical Corporation Control of vagal stimulation
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION RECHARGE SYSTEMS
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
CA3020346A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regimen
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
PL3579857T3 (pl) 2017-02-09 2022-07-25 Csl Behring Gmbh Produkt zastępujący czynnik krzepnięcia krwi do stosowania w leczeniu lub profilaktyce krwawień
EP3668402A4 (en) 2017-08-14 2021-05-19 Setpoint Medical Corporation VAGUS NERVOUS STIMULATION PRE-SCREENING TEST
CN112368028A (zh) 2018-05-09 2021-02-12 弗罗桑医疗设备公司 用于制备止血组合物的方法
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
EP4069835A4 (en) * 2019-12-03 2023-09-06 Omrix Biopharmaceuticals Ltd. PROTHROMBIN PURIFICATION
WO2021236977A1 (en) 2020-05-21 2021-11-25 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
AU2021348528A1 (en) 2020-09-23 2023-06-08 Omrix Biopharmaceuticals Ltd. Hemostatic formulations and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE350726C (de) * 1922-03-23 Henry Strauss Tintenloescher mit Loeschpapierblock
DE141262C (sl) *
DE382783C (de) 1920-01-27 1923-12-08 Gustav Pfarrius Verfahren zum Wasserabweisendmachen von Holz
AT350726B (de) * 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
DD141262B1 (de) * 1977-06-09 1984-02-29 Bezirks Inst Fuer Blutspende U Verfahren zur herstellung eines prothrombinkomplexkonzentrates
US4287180A (en) * 1980-01-28 1981-09-01 Baxter Travenol Laboratories, Inc. Method for treating blood clotting factor inhibitors
DE3172210D1 (en) * 1980-05-27 1985-10-17 Miles Lab Blood coagulation promoting product and process of preparing same
AT368883B (de) * 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
EP0286198B1 (en) * 1981-04-27 1994-12-14 BAXTER INTERNATIONAL INC. (a Delaware corporation) Blood clotting enzyme compositions
CA1181987A (en) * 1981-06-22 1985-02-05 Walter Crooks Print head for high resolution electrothermal printing apparatus
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US4721618A (en) * 1983-06-27 1988-01-26 Queen's University At Kingston Method for controlling bleeding
US4501731A (en) * 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5028424A (en) * 1987-10-16 1991-07-02 University Of Georgia Research Foundation Antibodies to receptor and antigen for natural killer and non-specific cytotoxic cells
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
JP2549224B2 (ja) * 1990-01-26 1996-10-30 イムノ・アクチェンゲゼルシャフト 組換えにより産生される血液因子及びその血液因子の発現方法並びにその方法に使用されるワクシニアウイルス組換え体
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
DE4142908C2 (de) * 1991-12-24 1994-02-10 Octapharma Ag Glarus Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB)
IT1262899B (it) * 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
WO1994020535A1 (en) * 1992-12-11 1994-09-15 Corvas International, Inc. ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
DE4325872C1 (de) * 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
FR2709227B1 (fr) * 1993-08-26 1995-10-20 Pellenc Sa Machine agricole, notamment machine de récolte telle que machine à vendanger.
DE4416180C2 (de) * 1994-05-06 1997-08-14 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
DE4430205A1 (de) * 1994-08-26 1996-02-29 Behringwerke Ag Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE59712322D1 (de) * 1996-03-20 2005-06-30 Baxter Ag Pharmazeutisches Präparat zur Behandlung von Blutgerinnungsstörungen

Also Published As

Publication number Publication date
HU9700603D0 (en) 1997-05-28
AU763466B2 (en) 2003-07-24
AU2003204479B2 (en) 2006-02-23
EP0796623A3 (de) 2000-05-17
US6165974A (en) 2000-12-26
AU2003204479A1 (en) 2003-06-26
CA2200394A1 (en) 1997-09-20
US6224862B1 (en) 2001-05-01
DK0796623T3 (da) 2005-08-01
AU725442B2 (en) 2000-10-12
AU7185600A (en) 2001-02-01
US6099837A (en) 2000-08-08
EP0796623B1 (de) 2005-05-25
EP0796623A2 (de) 1997-09-24
US5866122A (en) 1999-02-02
ES2241030T3 (es) 2005-10-16
CZ81997A3 (en) 1997-10-15
ATE296109T1 (de) 2005-06-15
AU1645197A (en) 1997-09-25
US6039945A (en) 2000-03-21
DE59712322D1 (de) 2005-06-30
HUP9700603A1 (hu) 1999-06-28
HUP9700603A3 (en) 2001-08-28
JPH1045620A (ja) 1998-02-17

Similar Documents

Publication Publication Date Title
HU9700603D0 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
EP0541507A2 (de) Thrombin sowie Verfahren zu seiner Herstellung
GR82018B (sl)
IL135712A0 (en) Methods for treating hypercoagulable states or acquired protein c deficiency
FR2679251B1 (fr) Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
GR3001151T3 (en) Dressing for the treatment of wounds and manufacturing process
JP3032085B2 (ja) プロテインｃを含有し血栓溶解活性を有する非経口投与が可能な薬剤
AU6567086A (en) Compositions and methods for the treatment of bleeding disorders
EP0101935A1 (de) Verfahren zur Herstellung des C1-Inaktivators und seine Verwendung
ATE257378T1 (de) Phenylacetylglutamin, phenylacetylisoglutamin, und/oder phenylacetat zur behandlung von neoplastischen erkrankungen
AU696954B2 (en) Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications
AU4727889A (en) A novel purified thrombomodulin-like glycoprotein obtained from urine.
FI873905A0 (fi) Terapeutisk komposition och foerfarande.
EP0297294A1 (de) Verfahren zur Herstellung einer Lösung hoher spezifischer Volumenaktivität von einem Protein mit Gewebe-Plasminogenaktivator (t-PA)-Aktivität, Lösung, enthaltend Protein mit t-PA-Aktivität und Verwendung der Lösung in der Human- und Veterinärmedizin
DK0497956T3 (da) Præparater med reguleret frigivelse
EP0137356A3 (en) Covalently bound heparin - antithrombin-iii complex, method for its preparation and its use for treating thromboembolism
KR930009612A (ko) 바이러스-유리된 트롬빈 농축물 제조방법
DE59310192D1 (de) Ligninpolymerzusammensetzung zur Behandlung von Hautproblemen
Honorato Human blood serum rich in factor V
AT406824B (de) Immuntolerante prothrombinkomplex-präparation
RU2128518C1 (ru) Способ лечения инфицированных ран
ATE234620T1 (de) Verwendung von lithium-gluconat zur herstellung eines arzneimittels zur behandlung von herpes und seborrhoischer dermatitis
Shampo et al. Stamp vignette on medical science
EP0282844A3 (en) Use of dopamine-agonists in the preparation of a medicament for the treatment of bone injuries
Sakuragawa et al. INTERACTION BETWEEN CULTURED ENDOTHELIAL CELLS AND ABNORMAL ANTITHROMBIN III